3Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activ [ 3 ] Schmidt-Woff GD, Negrin RS,Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3+ CD56+ killer cells[J]. Ann Hematol, 1997,74:51.
4Schmidt-Wolf IC, Lefterova P, Johnston V, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells[J]. Cell Immunol, 1996,169:85.
5Hoyle C, Bangs CD, Chang P, et al. Expansion of philadelphia chromosome-negative CD3( + )CD56( + ) cytotoxic cells from chronic myeloid leukemia patients:in vitro and in vivo efficacy in severe combined immunodeficiency disease mice[J]. Blood, 1998,92:3318.
6Schmidt-Wolf IG, Finke S,Trojaneck B, et al. Phase Ⅰ clinical study applying autolognus immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer , colorectal cancer and lymphoma[J]. Br J Cancer, 1999,81 : 1009.
7Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells [ J ]. Exp Hematol,1993, 21: 1673.
8Lu PH, Negrin RS. A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency [J]. J Immunol,1994, 153: 1687.
9Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells [J]. Blood, 1995, 86:3493.
10Hongeng S, Petvises S, Worapongpaiboon S, et al. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells[J]. Int J Hematol, 2003, 77(2): 175-179
